Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ.
Yee KW, et al. Among authors: gordon gb.
Clin Cancer Res. 2005 Sep 15;11(18):6615-24. doi: 10.1158/1078-0432.CCR-05-0650.
Clin Cancer Res. 2005.
PMID: 16166440
Clinical Trial.